remove_red_eye 498 Views
Not an eMediNexus Member?Register here.
Already registered?Login here.
Swachh Bharat has led to reduced ground water contamination
Union Minister for Jal Shakti Shri Gajendra Singh Shekhawat released two independent third-party studies conducted on the Swachh Bharat Mission (Grameen) on Wednesday. These studies, commissioned by UNICEF and the Bill and Melinda Gates, were aimed at assessing the environmental impact and communication footprint of the Swachh Bharat Mission (Grameen) respectively. The full reports as well as the summary reports of both the studies can be downloaded from mdws.gov.in and sbm.gov.in.
Environmental Impact study by UNICEF
Under the "Environmental impact of the Swachh Bharat Mission on Water, Soil, and Food" by UNICEF, groundwater samples were collected and studied from ODF and non-ODF villages of Odisha, Bihar and West Bengal. The study found that, in terms of faecal contamination, non-ODF villages were, on average:
The study findings indicated that these substantial reductions may potentially be attributed to the improvement in sanitation and hygiene practices, as well as supportive systems such as regular monitoring and behaviour change messaging, which have all been critical aspects of the Swachh Bharat Mission (Grameen).
IEC footprint study by Gates Foundation
The “Assessment of the reach and value of IEC activities under Swachh Bharat Mission (Grameen)” conducted by Dalberg, supported by the Bill and Melinda Gates Foundation, estimated the scale of IEC activities within the Mission and assessed associated monetary and in-kind costs, and outputs such as reach. The study found that:
(Source: Press Information Bureau, Ministry of Drinking Water & Sanitation, June 5, 2019)
Irregular sleep patterns linked to metabolic disorders
(NIH): A new study has found that not sticking to a regular bedtime and wakeup schedule — and getting different amounts of sleep each night — can put a person at higher risk for obesity, high cholesterol, hypertension, high blood sugar and other metabolic disorders. In fact, for every hour of variability in time to bed and time asleep, a person may have up to a 27% greater chance of experiencing a metabolic abnormality.
Researchers followed 2,003 men and women, ages 45 to 84, participating in the NHLBI-funded Multi-Ethnic Study of Atherosclerosis (MESA).
Individuals with greater variations in their bedtimes and in the hours they slept had a higher prevalence of metabolic problems, and these associations persisted after adjusting for average sleep duration. This was also the case when they looked at the participants who developed metabolic disorders during the 6.3 years of follow up.
The prospective results showed that the variations in sleep duration and bedtimes preceded the development of metabolic dysfunction. According to the authors, this provides some evidence supporting a causal link between irregular sleep and metabolic dysfunction.
Participants whose sleep duration varied more than 1 hour were more likely to be African-Americans, work non-day shift schedules, smoke and have shorter sleep duration. They also had higher depressive symptoms, total caloric intake, and index of sleep apnea.
The results of the study, which was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health are published in the journal Diabetes Care.
Healthcare News Monitor
As per Medical Council of India (MCI) ethics regulation 2.1, every doctor has an obligation towards the sick: “Though a physician is not bound to treat each and every person asking his services, he should not only be ever ready to respond to the calls of the sick and the injured, but should be mindful of the high character of his mission… A physician advising a patient to seek service of another physician is acceptable, however, in case of emergency a physician must treat the patient. No physician shall arbitrarily refuse treatment to a patient…” Regulation 2.4 says: “The patient must not be neglected: A physician is free to choose whom he will serve. He should, however, respond to any request for his assistance in an emergency….” In an emergency situation, the only answer is a modern medicine doctor or one registered with the Medical Council of India.
The WHO defines burn-out as a syndrome conceptualized as resulting from chronic workplace stress that has not been successfully managed. It is characterized by three things: feelings of energy depletion or exhaustion; increased mental distance from ones job, or feelings of negativism or cynicism related to ones job; and reduced professional efficacy. The need of the hour is to raise awareness on managing stress through lifestyle changes and balance. Speaking about this, Padma Shri Awardee, Dr KK Aggarwal, President, HCFI, said, "Burnouts due to work-related stress are becoming increasingly common especially in the corporate sector. While some workplace stress is normal, an excess of it can interfere with an individuals productivity and performance, impact their physical and emotional health, and affect their relationships and home life. It can even mean the difference between success and failure on the job. Job stress also raises the risk of heart disease by disrupting the bodys internal systems. Stressed workers tend to eat unhealthy, smoke, drink and skip exercise – all behaviors that are linked to heart disease. Conflicting priorities between work and home
Business Standard- Gireesh Babu
Mumbai-based online pharmacy and healthcare start-up PharmEasy may soon close a $100 million Series D funding from existing investors. The proceeds will be used to support customer acquisition and technology enhancement. The company is expecting a break-even in 24-30 months. The new round is expected to see participation from Avendus Capital, Eight Roads Ventures India, F-Prime Capital, Nandan Nilekani and Sanjeev Aggarwals Fundamentum Partnership and Think Investments, said sources privy to the talks.
Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator for Carbidopa and Levodopa extended-release tablets, used for treatment of Parkinsons disease. The approved product is therapeutically equivalent to the reference listed drug Sinemet CR tablets of Merck Sharp & Dohme Corp. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application Carbidopa and Levodopa extended-release tablets in the strengths of 25 mg/100 mg and 50mg/200 mg, Alembic said in a BSE filing. Quoting IQVIA sales data, the company said the Carbidopa and Levodopa extended-release tablets had an estimated market size of USD 24 million for 12 months ended December 2018.
Most of the state drug controllers regulators seem to be reluctant to take action on the circular issued by the Drugs Controller General of India (DCGI) on May 16 against drug manufacturers who continue to retain their old brand names after changing the active pharmaceutical ingredients (APIs) of their formulations. Except the DCs of Himachal Pradesh, Uttar Pradesh and Odisha, no state drug controllers’ offices have come with a positive response on the circular. While some of the drug controllers have stated that it is too difficult to find out the compositions the changed formulations, some others are of the opinion that no such product is moving in their markets. This shows that the state DC offices are not taking any action on the issue raised by the national drug regulator.
Pharmabiz- Shardul Nautiyal
The treatment of severe psoriasis has undergone a revolution with the advent of biologic therapies coupled with advances in research pathophysiology over the past decade, according to experts. Today, Biologic drugs are considered the most effective treatment options for severe psoriasis. Psoriasis is a common, non-contagious, autoimmune disease that affects more than 125 million people worldwide. Nearly one-fourth of people living with psoriasis, suffer from moderate to severe psoriasis. When psoriasis affects more than 10% of the body, it is considered as severe psoriasis, as per International Federation of Psoriasis Associations (IFPA). Additionally, severity of the condition and Body Surface Area (BSA) are used together as parameters to calculate the Psoriasis Area and Severity Index (PASI) score. A score of more than 10 generally translates to ‘moderate-to-severe’ psoriasis.
The Karnataka Innovation and Technology Society (KITS) of Department of Information Technology and Biotechnology, Government of Karnataka, has led a delegation to Philadelphia, Pennsylvania to participate in BIO 2019, one of the largest biotechnology expos in the world. The event which was held from June 3 to 6, 2019 had representations including six bio-start-ups under capacity building through exposure visits and workshops of the Karnataka Start-up Policy. The US convention held in June annually has been an important platform for the Department of IT, BT and S&T to showcase the state’s biotechnology ecosystem and learn more about the global perspectives. “Since 2013, we have been participating through the Biotechnology Facilitation Cell (BFC) along the Vision Group for BT, biotech companies, and researchers from top institutes across India,” said Dr. S Balasubramanya, Sr. Consultant (Biotech), KITS, Karnataka Dept. of IT, BT & S&T.
Africa is on track to become the fastest growing pharmaceutical market in the world over the next decade. The tropical climate of Africa makes the continent the largest reservoir of infectious diseases, particularly malaria and tuberculosis (TB) according to Seemeen Chandrantooty, AGM, Regulatory affairs Mylan Labs. The four factors driving the demand for pharmaceutical products in Africa are large number of cases of acquired immune deficiency syndrome (AIDS), besides frequent outbreaks of polio, meningitis, cholera, pandemic influenza, yellow fever, measles, hepatitis, and tetanus. Lifestyle diseases such as cardiovascular diseases, diabetes, and cancer will witness high growth rates throughout the forecast period. This leads to an increased requirement of drugs for ARV & infectious disease, hepatitis, antibiotics, oncology & immunology, he added.
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, announced that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s ataxia. This first patient was dosed at the end of April at the Hospital La Paz (Madrid) by a team headed up by Dr. Francisco Javier Rodríguez de Rivera. Additional sites, led by Prof. Alexandra Durr (ICM, Paris, France), Dr. Alexandra Darling (Hospital Sant Joan de Déu, Barcelona, Spain), Prof. Massimo Pandolfo (Hôpital Erasme-ULB, Brussels, Belgium), and Prof. Jörg Schulz (Universitätsklinikum RWTH, Aachen, Germany) are now also open for enrollment. FRAMES is a double-blind, placebo-controlled trial with the aim of assessing the efficacy and safety of leriglitazone in Friedreich’s ataxia patients. Principal investigator is Professor Alexandra Durr from the Brain and Spine Institute of La Pitié-Salpêtrière University Hospital (ICM), Paris. The trial will enroll 36 patients aged 12 years or older with a treatment duration of one year.
Illumina, Inc announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu. VeriSeq NIPT Solution v2 delivers the most comprehensive view of the fetal genome compared to other CE-IVD NIPT products, enabling healthcare providers to support expectant parents with informed, timely and personalized pregnancy management options better than ever before. VeriSeq NIPT Solution v2 is now available across most countries in Europe, as well as South Africa. Product registration is pending in Australia, Israel and New Zealand. Illumina, Inc announced the launch of VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). The automated comprehensive solution allows laboratories to screen for a broader range of chromosomal and sub-chromosomal conditions associated with birth defects and adverse pregnancy outcomes than the standard NIPT menu.
AbbVie, a research-based global biopharmaceutical company, presented data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with CLL and coexisting medical conditions. The results demonstrate that venetoclax plus obinutuzumab prolonged progression-free survival (PFS) and achieved higher rates of complete response and minimal residual disease (MRD)-negativity compared to a commonly used standard of care obinutuzumab plus chlorambucil. These data were presented in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and were simultaneously published in the New England Journal of Medicine (NEJM). "Conducting CLL14 was another collaborative and bold attempt to continue pushing the boundaries of treatment in CLL," said Mohamed Zaki, M.D., Ph.D., vice president, global head of hematology development, AbbVie. "The combination of venetoclax plus obinutuzumab significantly prolonged progression-free survival and patients maintained that benefit after stopping treatment. After the recent approval in the US, we look forward to continue working with health authorities worldwide as we aim to bring venetoclax plus obinutuzumab to patients with previously untreated CLL."
Pristyn Care has raised US$ 4 million in Series A funding from Sequoia India to improve its medical capabilities, invest in technology and expand its team of medical professionals. Pristyn Care is a healthcare delivery start-up that offers patients a range of elective surgeries across proctology, gynaecology, urology and ENT, Currently operational in 20 clinics across Delhi, Bengaluru and Hyderabad, it plans to expand its network to 50 by December 2019. Till date it has facilitated over 2000 surgeries, performed by a team of experienced doctors specialising in the areas of minimal access surgery, laser, cosmetic & aesthetic gynaecology, laparoscopic surgery, infertility and onco-gynaecology.
Boehringer Ingelheim and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release (XR) for the treatment of adults with type 2 diabetes. "Millions of adults with type 2 diabetes take multiple medicines to control their condition," said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "If approved by the FDA, the combination tablet would be one of the first single-pill options with three complementary mechanisms of action to help manage blood glucose in adults with type 2 diabetes who could benefit from having empagliflozin and linagliptin as part of their treatment regimen, in addition to metformin."
The German technology group SCHOTT is investing an additional double-digit million-euro figure into a new glass tank at its tubing manufacturing plant in Jambusar, Gujarat. The expansion follows recent investments at the site including the construction of another additional tank facility just last year. Production of pharmaceutical FIOLAX tubing from the new tank is scheduled to begin in the second half of 2020. The capacity expansion is part of the company’s global growth strategy of its pharma tubing and packaging business segments. “The pharmaceutical market is booming worldwide with a very high demand for premium pharmaceutical packaging and tubing”, comments Dr. Patrick Markschlaeger, Executive Vice President at SCHOTT, Business Unit Tubing. “In order to supply the rapidly growing domestic and Asian market, we are investing once again a multimillion-euro figure in our Jambusar site to increase our manufacturing capacity in India.”
Health Issues India- Nicholas Parry
It was thought, due to the state government’s effective response to an outbreak of the disease last year, that the virus was a problem of the past. This recent case may indicate otherwise. Due to the disease being transmitted to humans from animals it is possible that the virus is still prevalent in India even when no humans are currently infected. This opens up the possibility of constant resurgence. The response by the government has so far been both rapid and thorough. Fever clinics have been established and Kerala State Health Minister K. K. Shailaja has personally joined the ranks of those coordinating the containment process. Alongside her are a number of doctors present during the original outbreak last year — one that claimed the lives of seventeen people.
Medianama- Zaheer Merchant
Online pharmacies in India are a step closer to being formally recognised and regulated, with health ministry officials set to meet industry stakeholders on June 10 to finalise the rules governing them, Mint reported. The government released the draft rules as amendments to the Drugs and Cosmetics Act last August (read a copy here), and plans to roll them out in the first 100 days of its second term. Under the draft rules, only government-registered e-portals can sell medicines, and must retain prescriptions and verify details of patients and doctors.
The Times of India- Aamir Khan
The family of an aspiring doctor, who died of dengue while studying in the seventh semester at AIIMS in 2006, has been awarded Rs 50 lakh compensation. Raj Kiran Kamala, who had secured second rank in the AIIMS entrance medical examination, died at the medical institute’s ICU. The Delhi State Consumer Disputes Redressal Commission has found AIIMS to be “casual” in its approach and “taking things lightly as if life of the patient (Raj) had no value”. Noting that securing admission in MBBS in AIIMS was an extraordinary achievement, Commission member (judicial) O P Gupta said, “The parents of such a child had great hope that he would become a good doctor and have a respectable income. The death of such a child at the young age of 20 years is bound to cause shock and the family is likely to lose the hope of ray.” In 2003, Raj Kiran Kamala had secured second rank in the AIIMS entrance medical examination. While still a student at the institute he complained of fever and went to its emergency room on September 27, 2006. He was sent back to his room after a few hours though his condition required urgent attending as his hematocrit (blood concentration) count was 50%, platelets had come down to 1.05 lakh and he was having gastrointestinal bleeding. Dengue was common a viral infection with the symptoms of drastic reduction in hematocrit count. The next day, a resident doctor saw him and Kamala was advised hospitalisation after diagnosis of dengue hemorrhagic fever.
The Times of India
The Madurai bench of Madras high court granted permission to a doctor to appear for National Eligibility cum Entrance Test Super Specialty Courses (NEET-SS) exam to pursue DM Medical Oncology course. In his petition, Dr D Satheesh Kumar, a resident of Thanjavur district stated that he had completed MD Paediatrics during the year 2014 and was continuously preparing for the NEET-SS as he is aspiring to join DM Medical Oncology course. He submitted that as per Postgraduate Medical Education Regulation 2000, the requirement for joining DM Medical Oncology is to hold MD Medicine or MD Radiotherapy or MD Paediatrics. He submitted that he had appeared for the NEET-SS exam conducted during the year 2018 and secured 51st rank and was allotted a college in Mumbai to pursue DM Medical Oncology. But, he was not able to join the course due to personal reasons. However, in the year 2019, he was shocked to notice that the secretary of Medical Council of India, New Delhi, had issued Postgraduate Medical Education (Amendment) Regulation 2019, in which MD Paediatrics was omitted as a requirement to pursue DM Medical Oncology. He said that due to this, he was unable to submit an online application for the course. Hence, the petitioner prayed HC for a direction to declare the Postgraduate Medical Education (Amendment) Regulation 2019 as illegal. He also prayed to permit him to appear for the NEET-SS exam for DM Medical Oncology course.
The Times of India
A German nurse believed to be the most prolific serial killer in the countrys post-war history was handed a life sentence Thursday for murdering 85 patients in his care. Judge Sebastian Buehrmann called Niels Hoegels killing spree "incomprehensible". The 42-year-old murdered patients selected at random with lethal injections between 2000 and 2005, when he was caught in the act. Hoegel has already spent a decade in prison following a previous life sentence he received for six other murders. The exhumation and autopsy of more than 130 bodies were necessary to build the case for the prosecution. Police suspect that Hoegels final death toll may be more than 200. But the court was unable to say for sure because of gaps in Hoegels memory and because many likely victims were cremated before autopsies could be performed.
Hindustan Times- Ruchir Kumar
With the Bihar government considering granting autonomy to some of its health facilities, director of the Indira Gandhi Institute of Medical Sciences (IGIMS) has advocated banning private practice of government doctors while granting autonomy to healthcare institutions for improved patient care. The IGIMS, which is Bihar’s only autonomous medical institution, built on the pattern of the All India Institute of Medical Sciences (AIIMS), has achieved many milestones during the recent past. Seeing its success, the state government now wants to replicate the IGIMS model at five other healthcare institutions of Bihar.
Business Standard- PTI
Articular cartilage repair has been approached with a new perspective by orthopaedic experts from Parvathy hospital, by reducing the two-step surgery process and thereby reducing the cost of surgery approximately by 5 times. This case has been featured in the Asian Journal of Arthroscopy. Dr. Vetri Kumar, Consultant Knee surgeon of Parvathy Hospital, along with his 4 member team - surgeons from Italy and Poland performed this innovative technique - CARTILAGE REPAIR USING MESENCHYMAL STEM CELLS. This technique provides a new approach to articular cartilage repair in the form of Biological Arthroplasty. Osteoarthritis of the knee is the most common problem worldwide leading to disability. Almost 19% of population above 40 years and 50% of people above the age of 75 years in the world suffer from it. Over the years people diagnosed with osteoarthritis have offered the solution of knee replacement which helps the patient to lead a pain free but compromised life by avoiding jogging, squatting, playing sport. However, considering the new-gen middle age population who prefers to be active even at the age of 60 years, surgery using artificial prosthesis fails to satisfy them. Hence, orthopaedic surgeons along with biologist and researchers have been hunting for a biological solution for more than a decade.
The Indian Express- Sadaf Modak, Sagar Rajput
THE MUMBAI Police Crime Branch, which on Thursday got a nod from the Bombay High Court to interrogate the three doctors arrested in the Payal Tadvi suicide case, seeks to confront the accused with CCTV footage in which they are allegedly seen loitering near Tadvi’s room after she committed suicide on May 22, said police. “There are certain matters emerging from the CCTV footage which have to be investigated,” Special Public Prosecutor Raja Thakare told the High Court on Thursday.
ET Healthworld- Shahid Akhter
Taking care of the wound after a vascular reconstruction is as important as doing the vascular reconstruction itself. Wound care is a very neglected aspect of the treatment. At the end of a revascularization procedure, if the patient is left with a wound that doesn’t heal, it’s a procedure which has been wasted. Wound care management challenges today: Wound care management is a challenge, especially in the Indian scenario. The reason being that there aren’t many people in the Indian field who are really interested in taking up the challenge of healing a wound. So today, it is a great challenge in India. With the exponential increase in cases of diabetes in India, we are having a huge challenge in managing the foot complications of diabetes commonly called the diabetic foot.
The Hans India
The scarcity of water is daunting the patients and their attendants at the government hospital here. They have to fetch water from nearby shops and hotels. The water scarcity in the scorching summer became unbearable, they said. When The Hans India visited the hospital, the attendants poured out their woes. When contacted, the superintendent Balaraj admitted the issue and assured to address the issue immediately. Surprisingly, till date, the scarcity issue remained the same and no action was initiated. The poor patients and their relatives request the authorities to address the issue.
The Tribune- Manav Mander
As heatwave conditions continue to prevail in the city, hospitals are receiving an increased number of patients affected by heat. The Civil Hospital is receiving 4-5 cases of heatstroke daily. Dr Avinash Jindal, medical specialist at the hospital, said they had started receiving cases of heat illnesses. “People should stay hydrated. Lemon water mixed with sugar and salt is a perfect solution to the problem. In addition to this, people should avoid going out during afternoon. It is preferable to go out during early morning hours or after 6 pm. In case, one has to go out during day then it is advisable to carry an umbrella or a wet towel,” Jindal said. Dr Sandeep Sharma, Medical Superintendent of the Dayanand Medical College and Hospital, said as the temperature had started rising, the chances of heat-related illness would also increase.
Asian News International
The Kottayam Police has registered a case against three hospitals, including Kottayam Medical College and two other private hospitals after a woman claimed that her father died as he was denied treatment by the three hospitals. The case was filed based on a complaint lodged by K Renimol, who alleged that her father, Jacob Thomas - an H1N1 patient - was denied treatment by the three hospitals and died due to the alleged negligence. Speaking to media on Thursday, Renimol, a native of Idukki, said, "I dont want this to happen to anyone. I went to three hospitals and my father was alive since we were giving him chest compressions. But no one could save my father as no one attended to him. We were just sent from one hospital to another. I am approaching legal remedies."
Apex consumer commission NCDRC has directed a hospital in West Bengal and its doctor to pay Rs 3.4 lakh as compensation to the family of a 15-year old girl, who died due to delay in surgery, saying timely treatment would have increased her chance of survival. The girl was admitted to the hospital suffering from appendicular perforation and she was advised to seek treatment elsewhere. When her father expressed inability to shift her, the doctor conducted the operation later that night, saying there was no availability of a surgical team earlier. However, her condition deteriorated further and she was transferred to another hospital with ventilator support accompanied by the surgical team. The girl was declared dead the next day.
A case was registered on Thursday against a Government Medical College and two private hospitals here for allegedly denying admission to a 62-year-old man who died after being turned away by the hospitals, police said. The case was lodged on the basis of the complaint by the relatives of the patient, identified as Jacob Thomas of Keralas Idukki district, they said. The hospitals were charged under Indian Penal Code Section 3